Hepatitis C in a new era: A review of current therapies

P and T

Volumn 42, Issue 5, 2017, Pages 316-329

  Kish, Troy ^a   Aziz, Andrew ^a   Sorio, Monica ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BOCEPREVIR; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELBASVIR PLUS GRAZOPREVIR; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLYCOPROTEIN E1; GLYCOPROTEIN E2; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; RALTEGRAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TELAPREVIR;

BRADYCARDIA; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; CRYOGLOBULINEMIA; DECOMPENSATED LIVER CIRRHOSIS; DNA POLYMORPHISM; DRUG EFFICACY; ECONOMIC ASPECT; END STAGE LIVER DISEASE; ESOPHAGUS VARICES; GLOMERULONEPHRITIS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CELL CARCINOMA; LIVER GRAFT; MIXED INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RNA TRANSLATION; VIRUS HEPATITIS; VIRUS REPLICATION;

EID: 85018940028     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (78)

1. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61 (1 suppl):S45-S57.
2. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003-2010. Ann Intern Med 2014;160(5):293-300.
3. Centers for Disease Control and Prevention. Hepatitis C FAQs. October 17, 2016. Available at: www.cdc.gov/hepatitis/hcv/cfaq. htm#cFAQ22. Accessed December 10, 2016.
4. Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57(6):2164-2170.
5. Suda KJ, Halbur DJ, Hunkler RJ, et al. Spending on hepatitis C antivirals in the United States, 2009-2015. Pharmacother 2017;37(1):65-70.
6. Ray SC, Thomas DL. Hepatitis C. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th ed. Philadelphia, Pennsylvania: Saunders; 2015:1904-1927.
7. United Network for Organ Sharing. 2015 Annual Report. Available at: www.unos.org/about/annual-report. Accessed January 7, 2017.
8. National Institute of Diabetes and Digestive and Kidney Diseases. Liver transplant. April 2012. Available at: www.niddk.nih. gov/health-information/liver-disease/liver-transplant. Accessed January 7, 2017.
9. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61(1):77-87.
10. American Association for the Study of Liver Diseases/ Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. July 6, 2016. Available at: www.hcvguidelines.org. Accessed January 7, 2017.
11. Centers for Disease Control and Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62(18):362-365.
12. Sovaldi (sofosbuvir) prescribing information. Foster City, California: Gilead Sciences; August 2015.
13. Harvoni (sofosbuvir/ledipasvir) prescribing information. Forest City, California: Gilead Sciences; February 2017.
14. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
15. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
16. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
17. Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvirsofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous proteaseinhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
18. Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatol 2015;61:1793-1797.
19. Reddy KR, Bourliere M, Sulkowski MS, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatol 2015;62(1):79-86.
20. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, openlabel phase 2a cohort study. Lancet Infect Dis 2015;15:1049-1054.
21. Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatol 2016;64(4):1049-1056.
22. Abergel A, Asselah T, Metivier S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an openlabel, multicentre, single-arm, phase 2 study. Lancet Infect Dis 2016;16(4):459-464.
23. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015;149(6):1454-1461.
24. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
25. Manns M, Samuel D, Gane E, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16(6):685-697.
26. Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks [Abstract 0005]. Gastroenterol Hepatol (NY) 2015;11(6 suppl 3):1-23.
27. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-713.
28. Vemlidy (tenofovir alafenamide) prescribing information. Forest City, California: Gilead Sciences; November 2016.
29. German P, Pang P, West S, et al. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [Abstract 06]. Presentation at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, D.C., May 19-21, 2014.
30. Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir) prescribing information. North Chicago, Illinois: AbbVie Inc.; June 2016.
31. Technivie (ombitasvir, paritaprevir, and ritonavir) prescribing information. North Chicago, Illinois: AbbVie; June 2016.
32. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
33. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992.
34. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
35. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. October 22, 2015. Available at: www.fda.gov/Drugs/DrugSafety/ucm468634.htm. Accessed January 7, 2017.
36. Zeuzem S, Jacobson IM, Baykai T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-1614.
37. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology 2014;147(2):359-365.
38. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992.
39. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 2016;64(2):301-307.
40. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016;150(7):1590-1598.
41. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015;313:1223-1231.
42. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385:2502-2509.
43. Asselah T, Hassanein T, Qaqish RB, et al. P1345: A randomized, open-label study to evaluate efficacy and safety of ombitasvir/ paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis. Presentation at European Association for the Study of the Liver 50th International Liver Congress 2015, Vienna, Austria, April 22-26, 2015.
44. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015;63(3):581-585.
45. Olysio (simeprevir) prescribing information. Titusville, New Jersey: Janssen Therapeutics; May 2016.
46. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
47. Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016;64(2):370-380.
48. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016;64(2):360-369.
49. Daklinza (daclatasvir) prescribing information. Princeton, New Jersey: Bristol-Myers Squibb; February 2016.
50. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
51. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714-725.
52. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-1135.
53. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63(5): 1493-1505.
54. Zepatier (elbasvir/grazoprevir) prescribing information. Whitehouse Station, New Jersey: Merck and Co., Inc.; 2016.
55. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med 2015;163(1):1-13.
56. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct acting antiviral agent. J Hepatol 2015;63(3):564-572.
57. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C genotype 1 infection after failure of pegylated interferon and ribavirin with an earliergeneration protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis 2016;62(1):32-36.
58. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973):1087-1097.
59. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973): 1075-1086.
60. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545.
61. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE COINFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2(8):e319-e327.
62. Epclusa (velpatasvir/sofosbuvir) prescribing information. Foster City, California: Gilead Sciences, Inc.; 2016.
63. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373(27):2599-2607.
64. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373(27):2608-2617.
65. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373(27):2618-2628.
66. Brau N, Wyles D, Kottilil S, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study [Abstract WEAB0301]. Presentation at 21st International AIDS Conference (AIDS 2016), Durban, South Africa, July 18-22, 2016.
67. Red Book Online. Ann Arbor, Michigan: Truven Health Analytics. Accessed March 24, 2017.
68. Wyden R, Grassley CE; United States Senate Committee on Finance. The price of Sovaldi and its impact on the U.S. health care system. December 2015. Available at: www.finance.senate. gov/imo/media/doc/1%20The%20Price%20of%20Sovaldi%20 and%20Its%20Impact%20on%20the%20U.S.%20Health%20Care%20 System%20(Full%20Report).pdf. Accessed March 14, 2017.
69. National Viral Hepatitis Roundtable, Center for Health Law and Policy Innovation. Hepatitis C: The state of Medicaid access— Preliminary findings: National summary report. November 14, 2016. Available at: www.chlpi.org/wp-content/uploads/2013/12/ HCV-Report-Card-National-Summary_FINAL.pdf. Accessed December 10, 2016.
70. Linas BP. Understanding cost and value in hepatitis C therapy. Top Antivir Med 2016;24(2):93-97.
71. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-S29.
72. Bentley TS. 2014 U.S. organ and tissue transplant cost estimates and discussion. Milliman Research Report. December 2014. Available at: www.milliman.com/uploadedFiles/insight/ Research/health-rr/1938HDP_20141230.pdf. Accessed December 10, 2016.
73. Tapper EB, Catana AM, Sethi N, et al. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer 2016;122(6):852-858.
74. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-337.
75. Kralj D, Virovic JL, Stojsavljevic S, et al. Hepatitis C virus, insulin resistance, and steatosis. J Clin Transl Hepatol 2016;4(1):66-75.
76. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type-2 diabetes in chronic hepatitis C. Hepatology 2009;49(3):739-744.
77. Hsu YC, Lin JT, Ho HJ. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014;59(4):1293-1302.
78. Poonsapaya JM, Einodshofer M, Kirkham HS, et al. New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison. Cost Eff Resour Alloc 2015;13:17.